Navigation Links
Intellectual Property Lawyer Available for Comment on Recent Supreme Court Ruling
Date:3/24/2012

BUFFALO, N.Y., March 23, 2012  /PRNewswire/ -- Jeremy P. Oczek, a registered patent attorney and Member in the Intellectual Property and Technology Group of Bond Schoeneck & King, is available to comment on the recent Supreme Court ruling that has significant implications for the medical and biotechnology industries.

In Mayo Collaborative Services v. Prometheus Labs, Inc., the Court unanimously ruled that a medicine dosing process that merely describes a "natural law" is not eligible for patent protection. Writing for the Court, Justice Stephen G. Breyer said Prometheus Laboratories' medical tests, designed to help doctors determine the most beneficial drug dosage by describing the correlation between metabolites in patients' blood and the likelihood that the dosage will be ineffective or harmful, were directed to laws of nature and therefore not eligible for patent protection. Justice Breyer cited Einstein's E=mc(2) formula and Newton's law of gravity as celebrated examples of natural laws that courts have long held are not patentable.

Mr. Oczek, a registered patent attorney in the Buffalo office of Bond, Schoeneck & King, PLLC, has litigated patent cases in federal courts throughout the United States. He has offered commentary on intellectual property issues for many national publications, including The National Law Journal, BNA's Patent, Trademark & Copyright Journal and Law360, and has published articles on intellectual property law in the Buffalo Law Journal, Sedona Conference Journal and Boston College Law Review.

Bond, Schoeneck & King, PLLC is a full-service law firm of more than 200 attorneys with offices in New York State, Kansas and Florida. For a complete list of practice areas and industries served, please visit www.bsk.com

To arrange a phone interview with Mr. Oczek, please contact Kim Parr, Director of Public Relations at Latorra, Paul & McCann at (315) 476-1646, ext. 225 or email kparr@lpm-adv.com

Links

Opinion by Justice Stephen G. Breyer:
http://www.supremecourt.gov/opinions/11pdf/10-1150.pdf

New York Times: Justices Back Mayo Clinic Argument on Patents:
http://www.nytimes.com/2012/03/21/business/justices-reject-patents-for-medical-tests-relying-on-drug-dosages.html?scp=1&sq=mayo%20v%20prometheus%20supreme%20court&st=cse

Wall Street Journal: Top Court's Patent Rejection Alarms the Biotech Industry:
http://online.wsj.com/article/SB10001424052702304724404577293390828369720.html?mod=WSJ_hp_LEFTWhatsNewsCollection

Jeremy P. Oczek:
http://www.bsk.com/attorneys/bio.cfm?ID=3009

Bond, Schoeneck & King:
http://www.bsk.com/

Contact:
Kim Parr
Latorra, Paul & McCann
(315) 476-1646, ext. 225
kparr@lpm-adv.com


'/>"/>
SOURCE Bond Schoeneck & King
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. PharmacoFore, Inc. Announces Appointment of Chief Medical Officer and Vice President of Intellectual Property
2. Ontario Institute for Cancer Research Announces Enhancements to its Intellectual Property Development and Commercialization Program
3. iPierian Expands Leadership Team With Experienced Business Development and Intellectual Property Executives
4. China YCT International Group, Inc. Announces That the State Intellectual Property Office of the Peoples Republic of China has Approved a Patent to its Operating Subsidiary, Shandong Spring Pharmaceutical Co. Ltd.
5. BIO Ventures for Global Health Chosen to Administer the GSK and Alnylam Intellectual Property Pool
6. Joint BioEnergy Institute Selects Surety's AbsoluteProof to Protect the Integrity and Legally Defend the Authenticity of its Scientific Intellectual Property
7. Finn, Warnke & Gayton Announces A New Service For Biotechnology Firms - A Platform To Sell Intellectual Property
8. Veteran Intellectual Property Team Joins Brown Rudnick
9. EPIX Pharmaceuticals, Inc. Announces the PRX-00023 Therapeutics CNS Program in Phase 2b/3 Will Be Part of the Intellectual Property Offered for Sale at the September 30, 2009 Auction
10. Epix Pharmaceuticals, Inc. Announces the PRX-08066 Therapeutics Program in Phase 2 for Respiratory Indication Will Be Part of The Intellectual Property Offered for Sale at the September 30, 2009 Auction
11. Hill-Rom Announces Sale of Negative Pressure Wound Therapy Intellectual Property
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/16/2017)... ... January 16, 2017 , ... ... Tibbetts Award from the U.S. Small Business Administration. The Tibbetts Award ... economic or social impact […] and are considered the best of the best ...
(Date:1/14/2017)... Diego, CA (PRWEB) , ... January 14, 2017 ... ... of Proximo™, a new service providing complete end-to-end genome assemblies to researchers around ... complete genomes eliminates a major obstacle in answering a wide range of scientific ...
(Date:1/13/2017)... , Jan 13, 2017 Research and Markets ... Manufacturing, Application - Global Forecast to 2021" report to their ... The ... from USD 3.39 Billion in 2016, at a CAGR of 26.3%. ... basis of product, manufacturing type, and application. Factors such as rising ...
(Date:1/13/2017)... ... 2017 , ... Two Kalamazoo entrepreneurs have launched AgTonik LLC ... farms, greenhouses and hydroponics operations use to increase yields and promote plant growth. ... of customers using this high grade fulvic acid extracted from a mineral deposit ...
Breaking Biology Technology:
(Date:12/15/2016)... LONDON , Dec. 14, 2016 "Increase ... mobile biometrics market" The mobile biometrics market is expected ... USD 49.33 billion by 2022, at a CAGR of ... by factors such as the growing demand for smart ... mobile transactions. "Software component is expected to ...
(Date:12/7/2016)... According to a new market research report "Emotion Detection and Recognition Market by ... Area, End User, And Region - Global Forecast to 2021", published by MarketsandMarkets, ... to USD 36.07 Billion by 2021, at a Compound Annual Growth Rate (CAGR) ... ... MarketsandMarkets Logo ...
(Date:12/6/2016)... 2016  Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) ... of €500.0 million principal amount of its 1.414% senior unsecured ... 2.425% senior unsecured notes due 2026. The ... 2016, subject to the satisfaction of customary closing conditions.  The ... The Company intends to use the net ...
Breaking Biology News(10 mins):